Board of directors

Martin LeBlanc
President, Personalized Medicine Partnership for Cancer
President and CEO, Caprion Proteomics Inc.

A co-founder of Caprion, Martin has led the development of Caprion’s proteomics technology platform to a profitable and rapidly growing service business in the field of drug discovery, biomarker development and personalized medicine. Caprion has sustained a growing number of strategic alliances with over 50 major pharmaceutical and biotechnology companies as well as with leading government agencies and academic institutions.  He also concluded successful acquisitions as well as the recent sale of Caprion to Chicago Growth Partners, a leading healthcare private equity firm.   Prior to Caprion, Martin began his professional career as a management consultant with McKinsey & Company. He then initiated his career as a biotech entrepreneur at Advanced Bioconcept, initially as Vice-President of Sales & Marketing and then as General Manager following the company’s acquisition by NEN Life Sciences (now part of Perkin-Elmer). Martin is currently a member of the Governing Council of the Canadian Institutes of Health Research (CIHR), and of the Board of Directors of Cytovance Biologics, Victhom Human Bionics, Montreal In-Vivo and the Atlantic Cancer Research Institute. Martin earned his bachelor’s degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.

Gerald Batist, MD
Co-director, Quebec – Clinical Research Organization in Cancer

Dr. Batist obtained his BSc from Columbia University and then went on to study medicine at McGill University. He completed an internship in New York City and his residency in Boston. He then completed a fellowship and a post-doctorate in medical oncology and in molecular pharmacology at the Bethesda National Cancer Institute. In 1985, he returned to McGill University, first at the Montreal General Hospital, then at the Jewish General Hospital. He is named “Chercheur de mérite national” by the FRQS and maintains an active laboratory in molecular pharmacology. In 1996, he founded the McGill Center for Translational Research in Cancer (now the Montreal Centre for Experimental Therapeutics in Cancer), where he is still the director. This centre includes several laboratories and platforms for integrating translational research. In 2001, he was nominated Chair of the Department of Oncology at McGill University, where he established a large number of highly innovative multidisciplinary programs. Further to a prestigious award from the Canada Foundation for Innovation, he collaborated in the creation of the Segal Cancer Center in 2006 and remains its director. In 2007, he co-founded the Quebec – Clinical Research Organization in Cancer (Q-CROC). Dr. Batist holds the Minda de Gunzburg Chair in Oncology, is Professor in McGill University’s Departments of Medicine and Oncology, Director of the Segal Cancer Centre, and Director of the McGill Center for Translational Research in Cancer. He is a member of scholarly associations and serves on editorial boards and advisory committees. He has a highly successful laboratory and clinical research program and has authored over 180 scientific publications and a number of book chapters relating to his research interests. He has trained a numerous scientists and clinical oncologists, and continues to practice medical oncology.

David Levine
President and CEO, DL Consultation

David Levine is President of DL Consulting, a management consulting group, primarily in health care. President and CEO of the Montreal Health and Social Service Agency for 10 years (until 2012), President and CEO of the Ottawa Hospital (1998-2001), President and CEO of Notre-Dame Hospital in Montréal (1992-1997), President and CEO of the Verdun General hospital (1982-1992), and CEO of the Local Community Health Center in downtown Montreal (1975-1977), he was also Junior Minister of Health for the province of Québec (2002), Delegate General in New York for the Québec Government (1997-1998), Associate Vice-President, prevention, at the Commission of Occupational Health and Safety as well as Economic Adviser to the Minister of State for Economic Development (1977-1980). Mr. Levine has a Bachelors degree in civil engineering form McGill University (1970), a Masters of Philosophy in Bio Medical engineering from Imperial College, London, England (1972), and a Masters in Health Administration from the University of Montreal (1975(. Mr. Levine has been President of the Association of Teaching Hospitals of Canada, President of the Association of CEO’s of Québec, a Board Member of the Ontario Hospital Association, the Québec Hospital Association, and the Canadian Institute of Health Information. Mr. Levine is currently Adjunct Professor in the department of Family Medicine at McGill University, Clinical Professor in the Department of Health Administration at the University of Montreal, and giving a course in public administration at the University of Moncton. He has recently been named Chairman of the board of the Regroupement québécois en soins de santé personnalisés and member of the board of NEOMED.

Patrice Hugo, PhD
Chief Scientific Officer, Q2 Solutions a Quintiles and Quest Diagnostics Joint Venture

Patrice Hugo obtained a Ph.D. in Immunology from McGill University and conducted post-doctoral studies at the Walter and Eliza Hall Institute, Australia, and Howard Hughes Medical Institute, USA. In 1994, he was appointed as Principal Investigator and Head of the Lymphocyte Differentiation Laboratory at the Institut de Recherches Cliniques de Montréal. As of 1997, as VP and Chief Scientific Officer at PROCREA BioSciences, Dr. Hugo led the biomarker discovery program in reproductive medicine, resulting in the development of the world’s first diagnostic test for endometriosis and the commercialization of a paternity test. In 2003, Dr. Hugo joined Caprion, a world leader in mass spectrometry-based proteomics. As Executive VP R&D, he led the identification of diagnostic biomarkers and drug targets. In 2008, Dr. Hugo became VP Scientific Affairs at MDS Pharma Services – Global Central Laboratory, overseeing clinical testing and the validation and deployment of biomarkers assays. In 2009, the MDS Central Lab business was sold to Clearstone Central Laboratories where Dr. Hugo acted as Chief Scientific Officer. In 2011, Clearstone was acquired by LabCorp Clinical Trials, a company conducting over 1,000 clinical studies, and where Dr. Hugo acted as Associate VP and Chief Scientist, managing laboratories over 4 continents. In 2015, Dr Hugo accepted a position as Chief Scientific Officer of Q2 Solutions, a Quintiles and Quest Diagnostics Joint Venture. He is as well author or co-author of over 180 scientific manuscripts and communications.

Martine Hubert, M.D.
Director Medical Affairs, Oncology
Pfizer Canada Inc.

Martine Hubert received her Physician Diploma and Doctorate in Medicine from the “Université Louis Pasteur”, Strasbourg, France. During the course of her studies, Martine also gained professional experience as a nurse in oncology and in cardiovascular intensive care. Following her graduation, she practiced as a physician at several field and university hospitals, private practices and transfusion centers throughout Europe and Africa. In 1993, Martine moved to the US and continued her medical training in family practice at the outpatient department, University of Louisville Hospital, KY. In 1999, Martine permanently moved to Canada.
Martine has a strong experience in pharmaceutical medicine having worked at a number of companies in Canada. She has a broad functional experience in pharmacovigilance, medical information, field based and headquarter based medical roles. Martine has also worked in various therapeutic areas including, cardiovascular, metabolic, neurosciences and oncology. Before joining Pfizer, Martine worked at Lundbeck Canada Inc. where she was a Scientific Advisor in Oncology and Medical Scientific Liaison (MSL) team manager.
Of note, Martine has a tremendously strong passion for Oncology.

Joachim Le Garrec
Medical Advisor / Medical Science Liaison, Renal, Sanofi

Joachim Le Garrec has obtained his Chemical Engineering degree from l’École Polytechnique de Montréal and his Pharmacy doctorate from l’Institut des Sciences Pharmaceutiques de Lyon. Joachim started his carrier with SNC Lavalin Pharma as a consultant and then has worked at Pharmascience in the validation field.
He has joined Sanofi about 10 years ago were he has held various responsibilities in pharmacovigilance and as part of the medical affairs and the access departments. He has built an expertise in oncology, nephrology and bio-surgery.


Scientific Advisory Board

An international scientific advisory board has been put in place in order to assist the PMPC with strategic direction and integration of Quebec innovations with those taking place in other provinces and countries.

Fabien Calvo, MD, PhD
Scientific Director, Cancer Core Europe
Gustave Toussy Cancer Campus, France

On December 1st 2014, Professor Fabien Calvo joined the Grand Paris Gustave Roussy Cancer Campus Grand Paris as Scientific Director of the Cancer Core Europe Consortium. Established in July 2014, Cancer Core Europe brings together six European centers in the fight against cancer: Gustave Roussy (Villejuif – France), Cambridge Cancer Centre (Cambridge, England), the Karolinska Institute – KI (Stockholm, Sweden), the Netherlands Cancer Institute – NKI (Amsterdam, Netherlands), the Vall d’Hebron Institute of Oncology – the VHIO (Barcelona, Spain), the German Cancer Research Center – DKFZ and the National Center for Tumor Diseases – NCT (Heidelberg, Germany). The goal of this consortium, which is defined as a European platform for Cancer Research, is to ensure a continuum in Europe between clinical research and care for patients. Annually, the consortium takes on 60,000 new cases, provides 300,000 treatments, offers close to 1 million consultations and conducts over 1,500 clinical trials.

Professor Fabien Calvo is a medical oncologist and doctor of human biology. He teaches pharmacology at the University Paris Diderot (Paris 7) and practiced at St. Louis hospital. He is specialized in the biology and genomics of metastatic processes, translational research, pre-clinical pharmacology and early phase hematology and oncology clinical trials.

From April 2007 to September 2014, Pr. Fabien Calvo was Deputy Director General of the National Cancer Institute (INCa), where he oversaw research programs and innovation.

During this period, he was also director of the Cancer Institute of AVIESAN – a multi-organizational thematic institute that brings together Inserm, CNRS CEA, INRA, INRIA, IRD, the Institut Pasteur, as well as certain hospitals and university hospital centres.

In 2008, he represented France in the creation of the International Cancer Genome Consortium – ICGC, along with colleagues from the United States, Canada, the UK and Germany, and again, in 2011, with the creation of the Global Alliance for Genomics and Health – GA4GH.

Professor Fabien Calvo was previously Clinical Director of the Paris hospitals and is former visiting scientist at the National Cancer Institute in located in Bethesda (NIH / NCI / DTP, USA).

From 1995 to 2007, he was Director of the Clinical Investigation Centre (CIC) of the “Institut national de la santé et de la recherche médicale (Inserm)” at Saint-Louis Hospital (AP-HP center / Inserm), which he founded. He was also director of Inserm Unit 716 that works to identify new molecular targets for cancer treatment. He is a member of the Academic Council of the “post-graduate school Fundamental Basis of carcinogenesis” and has authored over 200 publications.

Geoffrey Ginsburg, MD, PhD
Director, Center for Applied Genomics & Precision Medicine, Duke University School of Medicine
Professor of Medicine and Pathology, Duke University Medical Center
Professor of Biomedical Engineering, Duke Pratt School of Engineering

Dr. Ginsburg is the founding director for the Center for Applied Genomics & Precision Medicine at the Duke University Medical Center. He is a professor of Medicine, Pathology, and Biomedical Engineering at Duke University. His work spans oncology, infectious diseases, cardiovascular disease and metabolic disorders, and his research is addressing the challenges for translating genomic information into medical practice using new and innovative paradigms, and the integration of precision medicine into health care. He is an internationally recognized expert in genomics and personalized medicine with over 200 published papers and funding from NIH, DOD, Air Force, DARPA, the Gates Foundation, and industry. Prior to Duke he was at Millennium Pharmaceuticals Inc. where he was vice president of Molecular and Personalized Medicine and responsible for developing pharmacogenomic and biomarker strategies for therapeutics.

He serves as an expert panel member for Genome Canada, as a member of the Board of External Experts for the NHLBI, as Co-Chair of the Institute of Medicine’s Roundtable on Genome-Based Research to Human Health, as a member of the advisory council for the National Center for Accelerating Translational Science, as co-Chair of the Cures Acceleration Network, co-chair of the IOM/NIH Global Genomic Medicine Collaborative, and as a member of the World Economics Forum’s Global Agenda Council on the Future of the Health Sector.

Ron Goeree
Professor, Department of Clinical Epidemiology &Biostatistics, McMaster University

Ron Goeree is a Health Economist who specializes in Health Technology Assessment (HTA). He spent 30 years at McMaster University, most recently as a Professor in the Department of Clinical Epidemiology and Biostatistics. He is the founding Director of the Programs for Assessment of Technology in Health (PATH) Research Institute at St Joseph’s Healthcare Hamilton. At McMaster’s Health Research and Methodology (HRM) Program, he developed an advanced decision analytic modeling course and founded the Field of Specialization for HTA. Ron has also been involved in developing and teaching several international workshops in HTA and economic modeling. He is a co-editor of the Value in Health journal, and sits on editorial boards for Medical Decision Making and the Journal of Medical Economics.

Peter Hirth, PhD
Life-Science Advisor
Founder and Former CEO, Plexxikon

Dr. Hirth has over 30 years of biotechnology and pharmaceutical discovery and development experience. He was a co-founder and CEO of Plexxikon were he built a novel, structure-guided drug discovery platform, which over the last ten years, has brought several NCEs into the clinic in a variety of indications. Most advanced from this portfolio is a V600E B-raf selective inhibitor that was FDA approved for metastatic melanoma together with a companion diagnostic and is sold under the brand name Zelboraf™. After Plexxikon was acquired in April 2011 by Daiichi Sankyo. Dr. Hirth agreed to stay for a two year transition period until April 2013.

Previously, he was at Sugen, Inc. from 1991 until 2000 and helped build the company from its inception and advanced several kinase inhibitors through clinical trials in oncology. Sutent was the first Sugen product to reach the market in renal cell carcinoma. After the acquisition of Sugen by Pharmacia Upjohn in 1999, Dr. Hirth stayed on to help with the integration until 2000. At Sugen, Dr. Hirth held several positions with increasing responsibilities, last as President. Prior to Sugen, Dr. Hirth was a vice president in research with Boehringer Mannheim where, among other responsibilities, he successfully led the company’s erythropoietin program to approval in 1989, sold under the name Recormon. Before joining Boehringer Mannheim, Dr. Hirth was a research scientist with the Max Planck Institute, following the completion of his post-doctoral work at the University of California, San Diego. Dr. Hirth received his Ph.D. in molecular genetics from Heidelberg University, Germany.

Dr. Hirth serves as a director on the Boards of Kolltan Pharmaceuticals in New Haven, CT, Alios Biopharma, in San Francisco, CA, Kinemed in Emeryville, CA and Afferent Pharmaceuticals in San Mateo, CA.

Tyron Hoover, MD, JD
Director, Biorepository Regulatory Support
MD Anderson Cancer Center

A native south Texan, Dr. Hoover attended Southern Methodist University and then graduated from the University of Texas Southwestern Medical School. He completed a general surgery internship in Dallas before completing a residency in pathology at Baylor University Medical Center. Having developed an interest in the legal and ethical aspects of medicine as a resident, he completed law school at SMU’s Dedman School of law in Dallas. A former trial lawyer in Florida, he served as the Medical Director of the Total Cancer Care project and the Tissue Core Facility at the H. Lee Moffitt Cancer Center in Tampa, where he was involved in the startup of a large-scale and multi-institutional translational biobanking effort. While in Tampa he co-directed the University of South Florida College of Medicine’s Scholarly Concentration in Law & Medicine. He then started de novo a translational cancer biobank for a contract research organization in Tennessee. A licensed physician in both Florida and Texas, he is a member of the Florida Bar, the American Association for Justice, and is board certified in Anatomic and Clinical Pathology. He is a member of the College of American Pathologists’ Texas House of Delegates and is active in other professional medico legal and biobanking organizations, including the American College of Legal Medicine and the International Society of Biological and Environmental Repositories. His current role includes facilitating the continued excellence of all aspects of biorepository efforts at MD Anderson.

Thomas J. Hudson, MD
President and Scientific Director, Ontario Institute for Cancer Research (OICR)

Dr. Thomas J. Hudson is President and Scientific Director of the Ontario Institute for Cancer Research (OICR), which focuses on translational research in prevention, detection, diagnosis and treatment of cancer.

Dr. Hudson is internationally renowned for his work in genomics and human genome variation. At the Whitehead/MIT Center for Genome Research, he led a team that generated physical and gene maps of the human and mouse genomes. Dr. Hudson has been a founding member of the International Haplotype Map Consortium, the Public Population Project in Genomics (P3G) and the International Cancer Genome Consortium. Dr. Hudson is a member of the Steering Committee of the Global Alliance for Genomics and Healt which is developing an international framework to allow genetic and clinical data to be collected, managed and shared in an effective, responsible, interpretive manner.

Dr. Hudson’s laboratory at OICR is involved in the study of genome variation that affects cancer predisposition, progression, and response to therapy. His main project focuses on the genetic architecture of loci associated with risk of colorectal cancer. Dr. Hudson has co-authored more than 250 peer-reviewed scientific publications.

Dr. Hudson is Professor in the Departments of Molecular Genetics and Medical Biophysics at the University of Toronto. He is a fellow of the Royal Society of Canada and an Officer of the Order of Canada.


List of collaborators

  • Adriana Aguilar, PhD, Jewish General Hospital, McGill Centre for Translational Research in Cancer, Segal Cancer Center
  • Dr. Mark Basik, Jewish General Hospital, McGill Centre for Translational Research in Cancer, Segal Cancer Center
  • Dr. Gerald Batist, , Quebec – Clinical Research Organization in Cancer (Q-CROC)
  • Dr. Luc Bélanger, Quebec – Clinical Research Organization in Cancer (Q-CROC)
  • Dr. Christian Couture, Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ)
  • Prof. Mélanie Bourassa-Forcier, PhD, Université de Sherbrooke
  • Dr. Louis Gaboury, Institute for Research in Immunology and Cancer (IRIC)
  • Prof. Jean Lachaine, PhD, Peripharm and University of Montreal
  • Prof. Sylvie Mader, PhD, Institute for Research in Immunology and Cancer (IRIC)
  • Dr. André Robidoux, Centre hospitalier de l’Université de Montréal (CHUM)
  • Dr. Alan Spatz, Jewish General Hospital, Segal Cancer Center
  • Dr. Bernard Têtu, Centre de Recherche en Cancérologie de l’Université Laval
  • Yann Joly, Ph.D., Director, Center of Genomics and Policy,  McGill University
  • Jean Lachaine, Ph.D., President, PériPharm and Faculty of Pharmacy, University of Montréal
Copyright © 2013 PMPC - All rights reserved - Website conception Könige communications